news cells under siege, Cas is deployed against invaders, usually bacteriophages. A Cas enzyme is a masterly gene-cutting engine. It uses two bound RNAs-guide and tracer strands-that are central to their activity. Cas innately interacts with DNA and generates clean double-stranded breaks at loci specified by the guide RNA. In June 2012, Doudna and Emmanuelle Charpentier, a microbiologist at Umea University in Sweden, set the scientific community astir when they reported in the journal Science how they transformed the bacterial defense strategy into a new way to modify genes by hand. A member of Doudna's team also figured out how to combine the activity of two of nature's CRISPR RNAs into a single-guide strand.
Doudna received the 2014 Lurie Prize in Biomedical Sciences awarded by the Foundation for the National Institutes of Health. Last fall, she and Charpentier each won a $3 million Breakthrough Prize for their CRISPR research. The honor was funded by several big names in technology,including the founders of Facebook, Google, and the DNA company 23andMe.
Other gene-modifying technologies have never generated the excitement surrounding CRISPR. Zinc finger nucleases can achieve double-stranded DNA breaks, as can transcription activator-like effector nucleases. But some biologists have complained that both types of nucleases can be finicky. Neither possesses the reliability or simplicity of CRISPR-Cas9, said MIT's Zhang.
His institution holds the only U.S. patent on CRISPR-Cas9 technology. The University of California and the Broad Institute of MIT and Harvard University are embroiled in an intellectual property dispute over which was first to develop the gene-editing system. Zhang insists the method emerged in his laboratory, not Doudna's. Corn said there is no question that Doudna and Charpentier were first.
Vakoc credits his graduate student, Junwei Shi, as the catalyst behind his lab's move to CRISPR-Cas9 last year. Their research allowed them to "rediscover" six key targets already known in acute myelogenous leukemia. With CRISPR-Cas9 it took about 2 weeks to uncover what had taken scientists using conventional methods 60 years to find. 
Targeted Therapy Makes Inroads in Medulloblastoma
By Charlie Schmidt Children with medulloblastoma, a rare brain cancer, face a challenging prognosis. Standard treatments have boosted 5-year survival rates beyond 80%, but depending on a child's age, side effects-especially from radiation to the brain and spinal cord-can be devastating. Younger children, with their rapidly developing nervous systems, can wind up with substantial cognitive deficits that make it difficult for them to live independently as adults. Scientists are therefore highly motivated to develop more targeted therapies that could limit the need for radiation-or at least delay it until a child becomes old enough to tolerate treatment without a major drop in IQ.
Last July, investigators reported considerable progress toward that goal. In two concurrent phase II clinical trials, treatment with a targeted drug called vismodegib, which is approved already for basal cell carcinomas of the skin, shrank or eliminated tumors in four of 43 treated patients for 2 months or more. And in 13 patients, vismodegib stopped tumor growth for 17 months.
The study was published in the Journal of Clinical Oncology. Vismodegib targets smoothened, a protein with key roles in the sonic hedgehog (SHH) signaling pathway that regulates organogenesis and neurodevelopment. About a third of all medulloblastoma patients have SHHdriven disease, meaning the pathway is hyperactivated to the degree that it drives abnormal cell growth. Lead study author Giles Robinson, M.D., is a pediatric neurooncologist at St. Jude Children's Research Hospital in Memphis, Tenn. He said that as expected, vismodegib worked only in the SHH patients and not in others with medulloblastoma caused by other genetic defects. "Not all the SHH cancers responded to smoothened inhibition, and that shows we still need to be more specific with our targets," he said.
Insights From Gorlin Syndrome
Medulloblastoma afflicts roughly 500 patients annually in the United States.
Once viewed as a single tumor entity, it's now regarded as four illnesses, "as distinct from one another as breast cancer is from colon cancer," said Yoon-Jae Cho, M.D., assistant professor of neurology and neurosurgery at Stanford University Palo Alto, Calif. Besides SHH, patients can fall into one of three other subgroups: the WNT subgroup, which has the best prognosis; the Group 3 subgroup, which has the worst; and the Group 4 subgroup, which is the most common type of medulloblastoma, accounting for roughly 40% of all cases.
The idea to test vismodegib in the SHH subgroup was based on the cancer's shared biology with Gorlin syndrome. Patients with that condition develop basal cell carcinomas throughout the body and are at high risk for SHH medulloblastoma. Gorlin syndrome typically results from inherited mutations in a gene that codes for PTCH1, a transmembrane protein in the SHH pathway. A tumor suppressor, PTCH1 normally prevents smoothened from becoming hyperactivated. When mutated, PTCH1 loses that ability. Therefore, smoothened transmits continual growth signals that prompt cells to form tumors. By blocking that signaling, vismodegib inhibits the SHH pathway and limits tumor growth.
PTCH1 mutations can also develop spontaneously in brain cells and produce SHH medulloblastoma without skin cancer. Patients who have these somatic (i.e., noninherited) mutations do not have Gorlin syndrome, but Robinson and colleagues predicted they would respond to vismodegib. Their study offers proofof-concept evidence to that effect. The cohorts included both SHH and non-SHH patients, and only SHH patients responded to the drug. But some did not: PTCH1 mutations cause only half the SHH medulloblastomas. The rest are induced by mutations that affect more downstream SHH proteins, including one known as SOFU, and different forms of a protein called GLI that migrate into the nucleus to activate the transcription of SHH target genes. In these types of SHH cancer, blocking smoothened has no effect, since the downstream proteins are driving abnormal cell growth. "That's the take-away message from the study," Robinson said. "We need to know specifically where the mutations are in the SHH pathway to identify likely responders to vismodegib treatment."
Alternative Targets
Meanwhile, scientists are investigating ways to inhibit the downstream proteins. In 2014, Cho and colleagues published findings in Nature Medicine showing that a small molecule called JQL inhibits the activity of bromo and extra C-terminal (BET) proteins that, in turn, regulate the transcription of SOFU and GLI. Developed initially to block transcription of the myc oncogene, previously thought to be untargetable, BET inhibitors such as JQL are now eagerly sought in drug development. JQL targets a BET protein called BRD4. Cho's research shows that in addition to blocking myc in multiple myeloma, JQL interferes with SHH signaling downstream of smoothened. Cho said that JQL or a different BET inhibitor might overcome resistance to vismodegib, both in the half of SHH patients with primary resistance to smoothened inhibition and in others who inevitably become resistant to it. "What we're really trying to do is hit the most downstream proteins such as GLI, which is responsible for the entire SHH transcriptional output," Cho said. "This is a novel way of targeting cancer in general. Instead of hitting kinases and upstream components, you target the transcriptional machinery. JQL is essentially an epigenetic drug."
Marcel Kool, Ph.D., senior scientist in the division of pediatric neurooncology at the German Cancer Research Center in Heidelberg, said phase II results with vismodegib offer crucial evidence that targeted therapy can work in medulloblastoma. But the drug has its drawbacks, he said, including potential side effects in the bones that could be problematic, especially for young children. Moreover, vismodegib doesn't work in patients with p53 mutations, he said, who tend to have highly aggressive tumors.
Scott Pomeroy, M.D., Ph.D., neurologistin-chief at Boston Children's Hospital, says a promising approach could be to combine smoothened inhibitors with other targeted therapies, including BET and PI3 kinase inhibitors. Pomeroy said toxic effects associated with drugs that act on gene transcription could be worrisome "since they could affect not just genes in the SHH pathway but many other genes as well." He added, "We're only now beginning to learn how well tolerated they are."
One significant limitation to clinical research in SHH medulloblastoma is that fewer than 150 new cases occur per year. According to Pomeroy, investigators are exploring the potential for multinational clinical trials that can recruit cases from throughout Europe and North America. Researchers held recent m e e t i n g s in Boston and Heidelberg, he said, to "strategize and come up with shared approaches. We need to increase nu m b e r s a n d get these trials done faster and more efficiently." The challenge with SHH medulloblastoma, he added, is that since current treatments save lives, parents tend to be reluctant to gamble with an experimental therapy. "People ask, 'When is all this new research going to pay off?'" he said. "And the answer is that it's paying off now, but not in a single step. We can't turn off the radiation machines yet-as we gain success with targeted treatments, we can peel back on radiation and chemotherapy, but this is going to be a sequential process." The PDQ Childhood Central Nervous System Germ Cell Tumor Treatment summary was revised to include results of the Children's Oncology Group study ACNS0122. This study evaluated neoadjuvant chemotherapy followed by radiation therapy for children with localized non-germinomatous germ cell tumors. The neoadjuvant chemotherapy regimen consisted of carboplatin/etoposide alternating with ifosfamide/etoposide. At the completion of induction chemotherapy, responding patients received 36 Gy of craniospinal radiation, with 54 Gy to the tumor bed. On the basis of central review of response to induction chemotherapy, 87% of patients showed either a partial response (PR) or a complete response (CR). For the 102 eligible patients in the study, 5-year event-free survival (EFS) was 84% ± 4%, and overall survival (OS) was 93% ± 3%. At 3 years, EFS was
